Sara A. Hurvitz, MD

High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.

Adding trastuzumab emtansine to tucatinib appears to significantly improve progression-free survival in patients with metastatic HER2-positive breast cancer, says Sara Hurvitz, MD, FACP.

Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.

Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.

Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.

Sara Hurvitz, MD, spoke about to recent approval of fam-trastuzumab deruxtecan-nxki in the second-line setting for patients with HER2-positive breast cancer.

A neuro-oncologist explains the prevalence of leptomeningeal metastases in HER2+ breast cancer and her preferred method of treatment.

A multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.

Improvements regarding the identification and management of radiation necrosis in patients with HER2-positive metastatic breast cancer.

The importance of forming partnerships with patients and understanding their preferences for therapy when establishing treatment algorithms for patients with HER2-positive metastatic breast cancer.

Sara A. Hurvitz, MD, and Julia A. LaBarbera, NP, of UCLA, highlight the safety and efficacy profiles of newer novel treatment options available for HER2-positive breast cancer and brain metastases.

Variables that impact decisions to treat HER2-positive breast cancer and brain metastases with radiation therapy and systemic therapy, and recommendations on using memantine following radiation therapy.

Treatment recommendations for patients with HER2-positive metastatic breast cancer, like Erika Rich, upon identification of lesions in the brain.

Adverse events commonly associated with chemotherapies used to treat HER2-positive metastatic breast cancer, and recommendations to help equip patients with knowledge about what to expect during their treatment journey.

Erika Rich, a patient with HER2-positive metastatic breast cancer, explains why she opted to pursue a second opinion about her diagnosis and treatment options and proactively research her disease.

Recommendations for deciding what information is most important to discuss with patients during initial treatment planning for HER2-positive metastatic breast cancer.

Julia A. LaBarbera, NP, reacts to the treatment approach used for a patient with HER2-positive metastatic breast cancer, and highlights the benefits of new subcutaneous injections of trastuzumab and pertuzumab that are available.

Radiation oncologist Kamran Ahmed, MD, comments on indications for using radiation therapy to treat patients with HER2-positive de novo metastatic breast cancer.

The rationale for treating Erika Rich, a patient with HER2-positive metastatic breast cancer, with docetaxel, trastuzumab, and pertuzumab.

Patient advocate Erika Rich compares initial symptoms that prompted her to seek a medical evaluation with symptoms commonly associated with HER2-positive metastatic breast cancer.